Digital Health and Therapeutics
Accelerator Network

COPD360Net’s Mission is to support the development and adoption of novel digital health tools, medical devices and therapeutics that treat COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease.

In order to advance the development of new medicines, or the repurposing of existing drugs, a new approach is needed. COPD360Net is designed to facilitate, review, and expedite clinical trials for new therapies, medical devices, and digital health tools. In addition, COPD360Net is focused on implementation science – facilitating discovery to delivery.

Why COPD360Net?

While important strides have been made in improving the care for those with COPD, the last regulatory approval of a new mechanism of action therapeutic in COPD was in 2011, and drug development remains focused on individuals with moderate to advanced airflow limitation (GOLD 2-4).

In order to advance the development of new medicines, or the repurposing of existing drugs, a new approach is needed. COPD360Net is designed to facilitate, review, and expedite clinical trials for new therapies and digital health tools. In addition, COPD360Net is focused on implementation science – facilitating discovery to delivery.

Ultimately, the network will serve as an accelerator to speed innovation through patient-centered evidence generation and enabling clinical adoption.

What is COPD360Net?

COPD360Net is a network of core COPD Foundation accredited centers and networks, experts in the field of COPD and related lung disease, and relevant subject matter experts (including a Health Economist assessing Patient preferences and Valuation of the COPDF pipeline, a psychosocial expert studying cognitive impairment in chronic disease, and Primary Care physicians).

COPD360Net is governed by a Steering Committee of clinical lead expert representatives from participating centers, key content experts, and people with COPD and caregivers. The initial pipeline will be selected by the Steering Committee in partnership with the relevant subject-matter experts and the COPD Foundation’s Community Engagement Committee (CenCo), a diverse patient and caregiver committee.

The goals for COPD360Net are to:

  • Accelerate the adoption and reimbursement of digital health tools
  • Accelerate the development of novel therapies, including promising repurposed or shelved molecules
  • Innovate clinical trial designs: target specific COPD sub populations, use new endpoints, and take a mostly remote digital trials approach
  • Translate trial findings and patient preference into practice to inform optimal care delivery and reimbursement

Seeking funds for a platform study in young "Pre-COPD"

One of the studies COPD360Net is focused on conducting is a platform trial in young patients with non-obstructive chronic bronchitis. We currently seek partners to fund this critical study that aims to generate evidence on commonly prescribed medications used to treat this highly symptomatic population.

A call to action to investigators, funding agencies, industry, and regulators to initiate treatment trials for these populations who are currently being treated without evidence has recently been published in the American Journal of Respiratory and Critical Care Medicine.

All potential proceeds from COPD360Net will be used to support the COPD Foundation mission.

COPD360Net Steering Committee Members

    President & Chief Scientific Officer
    COPD Foundation

    Ruth Tal-Singer, PhD

    Ruth Tal-Singer, PhD, President & Chief Scientific Officer at the COPD Foundation, is internationally recognized as an innovative, patient-focused, and highly analytical health care leader and clinical scientist with extensive R&D experience. She has a proven history of successfully leading international public and private partnerships and non-profit organizations through critical advancements and progress of clinical trials and large international observational cohorts. She is adept at building and maintaining global partnerships between pharma, patients, academia, advocacy groups and governments. Her wide-ranging technical and scientific knowledge comprises molecular biology, immunology, application of digital technology, and in vivo disease models. She has authored hundreds of peer-reviewed articles, including highly cited scientific publications that reported important insights on COPD (h-index 68). Until her retirement from GSK in 2019, Ruth was a long-time COPD Foundation collaborator and the founding Industry chair of the COPD Biomarker Qualification Consortium (CBQC). Since taking the helm of the COPD Foundation, she has been a powerful advocate for visionary thinking and transformative approaches to putting the patient at the heart of research, building internal medical and scientific expertise, and catalyzing action in partnership with like-minded global organizations. She is committed to science-fuelled research, emerging technology, and innovative approaches to preventing, diagnosing, treating, and ultimately finding a cure for COPD, bronchiectasis, and nontuberculous mycobacteria lung disease. Recent initiatives include the formation of COPD360Net®, the COPD Foundation’s digital health and therapeutics development accelerator network, the Community Engagement Committee (CEnCo), and Oxygen360.
    Head of COPD360Net Digital Health and Therapeutic Pipeline Working Group
    Associate Professor
    University of North Carolina at Chapel Hill
  • Jerry Krishnan, MD, PhD (EXECUTIVE COMMITTEE)
    Head of COPD360Net Care Delivery Science Working
    Professor of Medicine and Public Health Associate & Vice Chancellor for Population Health Sciences
    University of Illinois at Chicago
    Chicago, IL
    Co-Lead of Primary Care and Integrated Practice Working Group
    American Academy of Family Physicians
    Chief Medical Officer, DARTNet
    Head of COPD360Net Patient and Caregiver Engagement Working Group
    Patient Representative
    West Des Moines, IA
  • Juan P. Wisnivesky, MD, DrPH (EXECUTIVE COMMITTEE)
    Co-Lead of Primary Care and Integrated Practice Working Group
    Society of General Internal Medicine
    Professor, Department of Medicine, Icahn School of Medicine at Mount Sinai
    COPD360Net Project Lead
    COPD Foundation

    Cara B. Pasquale, MPH

    Cara B. Pasquale is the Senior Director of Research at the COPD Foundation and Project Lead for COPD360Net. Ms. Pasquale has been with the COPD Foundation since 2014 where she was focused on establishing and growing the COPD Patient-Powered Research Network and engaging with patient and caregiver partners. In her current role she oversees several research projects and is focused on building the COPD Foundation’s COPD360Net program. She is skilled at overseeing and managing complex projects and has several years of public health experience including working with researchers to translate their work into action, community interventions, systematic literature reviews and engaging stakeholders. Ms. Pasquale holds a Master in Public Health from George Washington University and is a certified project management professional (PMP).
  • Surya Bhatt, MD
    Associate Professor
    University of Alabama, Birmingham
  • Gerard Criner, MD
    Chair and Professor, Thoracic Medicine and Surgery
    Temple University
    Philadelphia, PA
  • MeiLan Han, MD, MS
    Professor of Medicine in the Division of Pulmonary and Critical Care
    University of Michigan
    Ann Arbor, MI
  • Karin Hoth, PhD, ABPP
    Associate Professor of Psychiatry
    University of Iowa Carver College of Medicine
    Iowa City, IA
  • Ravi Kalhan, MD
    Professor of Medicine (Pulmonary and Critical Care) and Preventive Medicine (Epidemiology)
    Northwestern University
    Chicago, IL
  • Jill Ohar, MD
    Professor, Pulmonary, Critical Care, Allergy, and Immunologic Medicine
    Wake Forest Baptist Health
    Winston-Salem, NC
  • Fernando Martinez, MD
    Bruce Webster Professor of Internal Medicine, Professor of Medicine, Professor of Genetic Medicine
    Cornell University
    New York, NY
  • Richard Mularski, MD, MSHS, MCR
    COPD Patient-Powered Research Network co-PI Representative
    Professor of Health Systems Science, KP Bernard J. Tyson School of Medicine
    Clinical Professor of Medicine, OHSU
    The Center for Health Research
    Kaiser Permanente Northwest, Portland, OR
  • Julia F. Slejko, PhD
    Assistant Professor
    Pharmaceutical Health Services Research
    University of Maryland School of Pharmacy
    Baltimore, MD
  • Robert (Bob) Wise, MD
    Professor of Medicine
    Johns Hopkins University
    Baltimore, MD

COPD360Net Partners and Collaborators:

ENA Respiratory

ENA Respiratory

The COPD Foundation and ENA Respiratory have partnered to accelerate the development of INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections, to be utilized by people with chronic lung diseases. INNA-051 becomes the second pipeline asset for COPD360Net. Click here to learn more.



The COPD Foundation and Exploristics are collaborating to utilize Exploristics’ innovative study simulation software platform KerusCloud to establish a more efficient and smarter data-driven approach to study design and protocol development. Click here to learn more.



The COPD Foundation and Renovion have partnered to accelerate the development of a novel nebulized therapy, ARINA-1, for the treatment of excessive airway mucus and inflammation in individuals with chronic obstructive pulmonary disease (COPD) and non-cystic fibrosis (CF) bronchiectasis. ARINA-1 becomes the first pipeline asset for COPD360Net. Click here to learn more.



The COPD Foundation and Savana, an international medical company that has developed a scientific methodology that applies Artificial Intelligence (AI) to unlock clinical value embedded within the free text of (EHRs), are partnering to accelerate innovative clinical research into COPD. Learn more here about the COPD Foundation- Savana partnership.

Who can I contact about COPD360Net?

Cara Pasquale, Project Lead for COPD360Net at

Please note that at this time we are only reviewing proposals for Phase II ready and beyond.